Stockreport

Akari Therapeutics Announces Positive Topline Results from Fully Recruited Phase II Study of Nomacopan in Bullous Pemphigoid Patients

Akari Therapeutics Plc - American Depositary Shares  (AKTX) 
US:NASDAQ Investor Relations: investor.akaritx.com/investor-relations
PDF Study achieved primary endpoint of no drug-related serious adverse events and main secondary efficacy endpoints with 7 of the 9 treated patients showing a rapid and clin [Read more]